Topic: inflammatory conditions
Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.
Ritu Lal co-founded GEn1E alongside Clint Webb in 2018, licensing a group of p38alpha kinase inhibitors from the University of Maryland, Baltimore.
The termination of the clinical trial and molecule follows slower-than-expected progress for RG6174.
Immuno-oncology biotech Five Prime has outlicensed a medication from its protein discovery platform exclusively to Belgium biopharma UCB.
Evelo Biosciences has just forged closer ties with a heavyweight academic partner for its monoclonal microbials R&D, which envisages using bacteria to fight disease.
The study linked synthetic oral endocannabinoid-mimetic anabasum to a statistically significant drop on a skin disease scale.
The series D follows fast after InflaRx established the potential of its anti-human complement factor C5a monoclonal antibody IFX-1 with phase 2 data.
The multiyear agreement positions Lilly to work with Topas on drugs that convey tolerance to antigens linked to inflammation or autoimmune diseases.
The outlay gives Lilly the rights to a drug designed to treat autoimmune diseases by boosting the number and activity of regulatory T cells.
Evelo Biosciences has raised $50 million to take its monoclonal microbials into the clinic.